OR WAIT null SECS
October 11, 2019
On Wednesday Nov. 6, 2019, Gregor Deutschle and Dr. Nicolas Eon, both from Schott, will share insights into ready-to-use solutions for complex biotech drugs.
The companies will collaborate to identify and develop in-vivo genome editing therapeutic candidates for genetic diseases, including hemophilia.
October 08, 2019
The collaboration focuses on baculovirus/Sf9 expression system for Prevail's pipeline of novel AAV9-based gene therapy programs neurodegenerative diseases.
September 26, 2019
GSK’s expanded R&D and manufacturing facility in Upper Merion, PA houses a new analytical lab and flexible manufacturing equipment, including single-use bioreactors.
September 25, 2019
The companies have advanced their collaboration to the next stage and will continue to develop a plant-based biosimilar candidate to Roche’s Rituxan.
September 16, 2019
The acquisition will enhance Lundbeck’s brain disease therapy portfolio as well as its antibody process and development capabilities.
The acquisition gives PPF a 19.2% stake in Autolus and provides a pipeline of cell therapy product candidates.
September 13, 2019
FDA approved the drug after a successful open-label study of children aged six to 11 years and living with the condition.
The companies will develop and commercialize a Phase III cell therapy candidate for treating chronic low back pain in a deal worth potentially $1 billion.
September 09, 2019
The new antibody, Citryll’s CIT-013, could offer new treatment options for various human diseases including lupus, vasculitis, pulmonary fibrosis, and organ damage due to sepsis.